BXP — Beximco Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- £240.90m
- £253.42m
- BDT49.12bn
Annual cashflow statement for Beximco Pharmaceuticals, fiscal year end - June 30th, BDT millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | BAS | BAS | BAS | BAS | BAS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 2.38 | 3.06 | 5.53 | 2.8 | 19.9 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 6,023 | 5,214 | 6,085 | 8,364 | 7,223 |
| Capital Expenditures | -2,558 | -2,939 | -2,710 | -2,235 | -3,029 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 33.8 | -4,741 | 93 | -172 | -639 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2,525 | -7,680 | -2,617 | -2,406 | -3,668 |
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -3,458 | 2,615 | -3,561 | -6,260 | -2,727 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 40.5 | 195 | -33 | -282 | 846 |